Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Acq. announced
Appointed director
BIOMARIN PHARMACEUTICAL INC (BMRN) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/31/2023 8-K Quarterly results
04/26/2023 8-K Quarterly results
02/27/2023 8-K Quarterly results
Docs: "BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business •VOXZOGO $169 Million Contribution Drives Record Full Year 2022 Total Revenues of $2.1 Billion"
01/11/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Relevant Slides from BioMarin Pharmaceutical Inc. J.P. Morgan 2023 Presentation",
"Relevant Slides from BioMarin Pharmaceutical Inc. J.P. Morgan 2023 Presentation"
12/21/2022 8-K Quarterly results
10/26/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
09/12/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/03/2022 8-K Quarterly results
Docs: "BioMarin Announces Record Revenues in Second Quarter 2022&#59; Increases Full-year 2022 Top and Bottom-line Guidance •VOXZOGO™ $34 Million Contribution Drives Total Revenues of $534 Million in the Quarter&#59; Total Revenues Grew 13% Year-Over-Year, Excluding Kuvan"
05/31/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/27/2022 8-K Quarterly results
Docs: "BioMarin Announces Record Revenues in First Quarter 2022"
02/23/2022 8-K Quarterly results
Docs: "BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates"
02/14/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "BioMarin Sells Priority Review Voucher for $110 Million"
12/15/2021 8-K Quarterly results
11/03/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
10/27/2021 8-K Quarterly results
Docs: "BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates"
07/28/2021 8-K Quarterly results
Docs: "BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates"
06/01/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/22/2021 8-K Quarterly results
12/18/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amended and Restated Bylaws"
11/05/2020 8-K Quarterly results
Docs: "BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million"
09/09/2020 8-K Regulation FD Disclosure  Interactive Data
08/04/2020 8-K Quarterly results
07/02/2020 8-K Quarterly results
06/01/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/19/2020 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister...
Docs: "SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"BioMarin Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $50 million of 1.25% Senior Subordinated Convertible Notes due 2027"
05/14/2020 8-K Quarterly results
04/29/2020 8-K Quarterly results
Docs: "BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million"
04/22/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/26/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy